Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI)+CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
  • Mayer, E.
  • Bidard, F. C.
  • Park, Y. H.
  • Janni, W.
  • Ma, C. X.
  • 외 15명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI)+CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
저자
Mayer, E.Bidard, F. C.Park, Y. H.Janni, W.Ma, C. X.Cristofanilli, M.Bianchini, G.Iwata, H.Fasching, P. A.Brufsky, A. M.Nowecki, Z.Pascual, J.Moreau, L.Chen, S. C.Karadurmus, N.Arizmendi, C.Fox, S.Miralles, M. SelviBartlett, C.Turner, N. C.
DOI
10.1016/j.annonc.2025.08.910
발행일
2025-09
유형
Meeting Abstract
저널명
Annals of Oncology
36